GLP-1RA therapy increases circulating vascular regenerative cell content in people living with type 2 diabetes
Brady Park(St. Michael's Hospital), Subodh Verma(St. Michael's Hospital), Aishwarya Krishnaraj(St. Michael's Hospital), David A. Hess(Western University), Adrian Quan(St. Michael's Hospital), Hwee Teoh(St. Michael's Hospital), Fallon Dennis(St. Michael's Hospital), Ehab Bakbak(The University of Queensland)
American Journal of Physiology-Heart and Circulatory Physiology
June 14, 2024
Cited by 17
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
New Markers of Inflammation and Endothelial Cell Activation
|Circulation|2003|733
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693
Endothelial cell control of thrombosis
|BMC Cardiovascular Disorders|2015|678